Connect with us

Health

Company halts production of cough syrup linked with acute injuries

Published

on

Spread The News

 

 

The Pharmaceutical Company which produces four cough syrup brands linked with acute kidney injuries and the death of 66 children in Gambia has stopped production of the deadly syrup.

The health minister of India’s Northern state of Haryana, Anil Vij disclosed this in a statement, adding that the company, Maiden Pharmaceutical has been ordered to stop production.

Recall that recently the World Health Organisation (WHO) issued an alert on the four cough syrups — Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup.

The WHO said the four products were identified in the Gambia, but may have been distributed through informal markets to other countries or regions.

READ ALSONAFDAC raises alarms over killer syrup in circulation

In a statement on Wednesday, Vij ordered a pause on manufacturing in the company.

The minister said about 12 flaws were found during a joint inspection conducted at the pharmaceutical company by India’s federal and state drug departments.

“A notice has been served to the pharma company directing that total production shall be stopped,” Vij was quoted as saying.

“Samples of the drugs mentioned by the WHO of Sonipat’s pharmaceuticals company were sent to the Central Drug Lab in Kolkata. The reports are not in yet. Action will be taken after that.”

The minister added that the Indian government was yet to get the complete information.

Advertisement

Meanwhile, the National Agency for Food and Drug Administration and Control (NAFDAC) has warned Nigerians against the use of the cough syrup brands.

Mojisola Adeyeye, NAFDAC director-general, said alerts have been sent to all healthcare providers and professional bodies on the agency’s database.

The NAFDAC DG also said measures have been put in place to prevent the entry of the deadly cough syrups into Nigeria.

 

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published.

Trending